TORONTO, Oct. 4 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in the area of buccal drug delivery, today announced that Dr. Jaime Guevara-Aguirre, of the Institute of Endocrinology IEMYR in Quito, Ecuador and one of the principal investigators in the Company's on-going clinical trials of Oral-lyn(TM), its proprietary oral insulin spray product, made a presentation of Oral-lyn(TM) clinical trials results at the 7th Hong Kong Diabetes and Cardiovascular Risk Factors - East Meets West Symposium on October 2, 2005. Dr. Guevara-Aguirre made an oral presentation of an abstract entitled "Addition of Oral-lyn(TM) at Mealtimes in Subjects with Type-2 Diabetes Maintained on Glargine + Metformin - A Comparison with Placebo". The abstract was coauthored by Professor Itamar Raz of Hadassah Hospital, Jerusalem, Israel (another Oral-lyn(TM) principal investigator) together with M. Kidron (also of Hadassah Hospital) and M. Dubinsky and J. Wainstein of Wolfson Hospital, Holon, Israel.
In addition, Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs, will be making the following poster presentations at the Drug Discovery to Drug Development Global Partnering and New Science symposium in Mumbai, India from October 5 - 7, 2005: -- "A Series of Open-label Studies Comparing Various Formulations of
Orally Administered Insulin (Oral-lyn(TM)) in Patients with Type-1
Diabetes Mellitus (DM)", a study coauthored by Dr. Jaime Guevara-
Aguirre, Marco Guevara and Jeannette Saavedra of the Institute of
Endocrinology IEMYR in Quito, Ecuador; -- "A 12-Day Comparison of Preprandial Humulin(R) vs. Oral-lyn(TM) in 10
Type 1 Diabetic Subjects Receiving Baseline Glargine Insulin Therapy",
a study coauthored by Dr. Jaime Guevara-Aguirre, Marco Guevara and
Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito,
Ecuador; and -- "Addition of Oral-lyn(TM) at Mealtimes in Subjects with Type 2 Diabetes
Maintained on Glargine + Metformin - A Comparison with Placebo," a
study coauthored by Professor Itamar Raz of Hadassah Hospital,
Jerusalem, Israel together with M. Kidron (also of Hadassah Hospital)
and M. Dubinsky and J. Wainstein of Wolfson Hospital, Holon, Israel.
"The continuing acceptance at these significant scientific symposia of Oral-lyn(TM) studies is indicative of the increasing recognition in the global scientific community of our product's potential for providing a vast improvement in the quality of life of patients with diabetes," said Anna Gluskin, the Company's President & Chief Executive Officer. "In addition, we welcome the increased exposure of Oral-lyn(TM) in the scientific communities in China and India, two potentially enormous markets for the product." About Generex Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex Web site at http://www.generex.com/.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward- looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act. DATASOURCE: Generex Biotechnology Corporation CONTACT: Shayne Gilliatt of Generex Biotechnology Corporation, +1-800-391-6755, +1-416-364-2551; or Ed Lewis of CEOcast, Inc., +1-212-732-4300, , for Generex Biotechnology Corporation Web site: http://www.generex.com/
|